FastBio Competitors

Vital was created to enable proactive, preventative, and accessible healthcare. We're starting with a radically disruptive approach to lab testing. Backed by many years of R&D by world-class scientists and engineers, we are a team of collaborators, re-engineering the nature of care delivery.

Genetesis's MCG assets were acquired by a strategic partner in Summer 2025.

Our 'sample to data' model offers one of the world’s largest commercial biorepositories and a full suite of preclinical molecular services and research tools to accelerate breakthroughs in genetics, drug discovery, biomarker research, and molecular diagnostics. BioServe's Global BioRepository provides leading academic and industry researchers with access to over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients across four continents. Utilizing BioServe's preclinical molecular services, researchers can identify genetic markers, validate drug targets and correlate clinical and molecular data to accelerate the development of new and safer drugs. BioServe's research tools division offers everything from from nucleic acids processing, DNA synthesis, high throughput sequencing and genotyping, genome wide-scans and gene expression analysis to ready-made large epidemiologically sound case-control studies. BioServe's customers include nearly every major pharmaceutical and biotechnology company, as well as top industry, academic, and government research institutions. Founded in 1989, BioServe has corporate headquarters in Beltsville, Maryland with operations in Hyderabad, India and Milan, Italy.